Literature DB >> 20621290

Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer cells.

Nicolas Dauguet1, Jean-Jacques Fournié, Rémy Poupot, Mary Poupot.   

Abstract

Lenalidomide, a daughter molecule of Thalidomide, and IMIDs are immunomodulatory drugs that have been described as having immunomodulatory properties and anti-tumor activity. The effect of Lenalidomide towards Peripheral Blood Mononuclear Cells (PBMC) has been studied and direct effects towards T cells have been described, such as an increase of interferon-gamma (IFN-gamma) and interleukin (IL)-2 production. As a consequence, it has been also described that IL-2 subsequently activates Natural Killer (NK) cells. Nevertheless, direct effects of Lenalidomide on NK cells from healthy volunteers have never been described, if searched. Here we show that Lenalidomide can inhibit the production of IFN-gamma by NK cells from healthy donors. It also modifies the phenotype of NK cells through a decrease of the expression of Killer cell Immunoglobulin-like Receptors (KIRs) and NKp46. However, we did not detect consequence of these phenotype modifications on the cytotoxic potential of NK cells. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20621290     DOI: 10.1016/j.cellimm.2010.06.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.

Authors:  Martin Schmidt-Hieber; Robert Dabrowski; Babette Aicher; Philipp Lohneis; Antonia Busse; Carola Tietze-Buerger; Birgit Reufi; Eckhard Thiel; Igor Wolfgang Blau
Journal:  Invest New Drugs       Date:  2011-07-13       Impact factor: 3.850

2.  NKp46-specific expression on skin-resident CD4(+) lymphocytes in mycosis fungoides and Sézary syndrome.

Authors:  Pierre Schneider; Louis-François Plassa; Philippe Ratajczak; Christophe Leboeuf; Laurence Verneuil; Maxime Battistella; Armand Bensussan; Martine Bagot; Anne Janin
Journal:  J Invest Dermatol       Date:  2013-07-30       Impact factor: 8.551

3.  Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer.

Authors:  Shancheng Ren; Chuanliang Xu; Zilian Cui; Yongwei Yu; Weidong Xu; Fubo Wang; Ji Lu; Min Wei; Xin Lu; Xu Gao; You Liang; Jian-Hua Mao; Yinghao Sun
Journal:  J Mol Med (Berl)       Date:  2012-03-16       Impact factor: 4.599

Review 4.  Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity.

Authors:  Anne-Sophie Chretien; Aude Le Roy; Norbert Vey; Thomas Prebet; Didier Blaise; Cyril Fauriat; Daniel Olive
Journal:  Front Immunol       Date:  2014-03-24       Impact factor: 7.561

Review 5.  Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.

Authors:  Massimo Giuliani; Bassam Janji; Guy Berchem
Journal:  Oncotarget       Date:  2017-04-04

6.  Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.

Authors:  Aude Le Roy; Thomas Prébet; Rémy Castellano; Armelle Goubard; Florence Riccardi; Cyril Fauriat; Samuel Granjeaud; Audrey Benyamine; Céline Castanier; Florence Orlanducci; Amira Ben Amara; Frédéric Pont; Jean-Jacques Fournié; Yves Collette; Jean-Louis Mege; Norbert Vey; Daniel Olive
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

7.  Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.

Authors:  Yukie Tsubokura; Hideaki Yoshimura; Atsushi Satake; Yutaro Nasa; Ryohei Tsuji; Tomoki Ito; Shosaku Nomura
Journal:  Immun Inflamm Dis       Date:  2022-09

8.  Novel immune modulators used in hematology: impact on NK cells.

Authors:  Stephanie Krieg; Evelyn Ullrich
Journal:  Front Immunol       Date:  2013-01-03       Impact factor: 7.561

Review 9.  NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies.

Authors:  Kanako Shimizu; Tomonori Iyoda; Satoru Yamasaki; Norimitsu Kadowaki; Arinobu Tojo; And Shin-Ichiro Fujii
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.